Can Liraglutide Help Patients With PCOS Lose Weight?


Liraglutide CAS No: 204656-20-2
Liraglutide
CAS No: 204656-20-2

On June 17, 2013 Endocrine Today reported at the ENDO 2013 meeting that Liraglutide demonstrated success as a weight loss treatment. Combined with the antidiabetic drug Metformin, Liraglutide was administered on a short term basis to women with polycystic ovary syndrome who were considered obese.

“Obesity is a great problem in women with polycystic ovary syndrome (PCOS) and we do not have a conventional satisfactory treatment for it. The most widely used drug is metformin for women with PCOS and metabolic disturbances, but it’s somehow not successful enough to curb obesity. That’s why we tried to use our experience with diabetes to test long-acting GLP-1 agonists for any effect on the PCOS population,” Jenterle Sever said in an interview.

Metformin CAS No: 657-24-9
Metformin
CAS No: 657-24-9

This study centered on these women with polycystic ovary syndrome, also known as PCOS, as this patient population struggles with both metabolic issues as well as weight loss frustrations. There were 36 women who participated in this randomized study, which lasted twelve weeks. The female participants were dosed with either 1.2 milligrams of Liraglutide (Victoza) as a daily subcutaneous dose, 1000 milligrams of Metformin twice daily or a combination of both medications. The average age of the female patients was 31.3 years old. Of the female participants who received the combination of both Liraglutide and Metformin 22 percent of these women lost more than 5 percent of their body weight. For the female patients who were dosed with Liraglutide there were 16 percent of these women who achieved a weight loss of greater than 5 percent of their total body weight. The patients who were administered Metformin alone did not experience any weight loss. Additionally, the patients in the combination treatment group showed a larger decrease in their BMI and the circumference of their waist. Adverse side effects were minor, and included some mild nausea for the patients who were dosed with Liraglutide alone or with Metformin.

With the patent for Victoza set to expire for Novo Nordisk on January 28, 2019 research and development is sure to commence. LGM Pharma provides the Liraglutide CAS# 204656-20-2 API , as well as Metformin CAS# 657-24-9, for research and development purposes. Clients can be assured of continuous support throughout the R& D process, as well as quality API products

 

Jenterle Sever interview: http://www.healio.com/endocrinology/highlights-from-endo-2013/liraglutide-metformin-combo-superior-to-either-treatment-alone-for-weight-loss-in-pcos

 

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share: